A significant amount of the additional 933 billion dollars that Americans spent on health care in 2013 compared to 1996 was because of higher rates of care and an increase in the number of people getting expensive care. According to a recent analysis posted in JAMA, aging and population growth are the two critical reasons for the increase in spending. The change in occurrence of diseases led to a minimal decrease in yearly spending, and the rate at which people visited healthcare facilities did not affect the outcome of the research.
According to Gerard Anderson of Bloomberg School of Public Health, people have always assumed that the increase in spending is due to higher costs. The overall finding isn’t new; the only difference is the breakdown of spending in the analysis, Says Anderson.
For instance, diabetes was the condition with the highest expenditure 64 billion dollars. About three-quarters of this amount (44 billion dollars) was spent on medication. All the factors that the study investigated had an impact on the increase in spending.
The research show that high costs cannot be used to justify the increase in healthcare spending; instead, prevention can help in reducing this cost.
About Eric Lefkofsky
Born on the 2nd of September 1969, Eric Lefkofsky is the CEO and co-founder of Tempus and chairman and co-founder of Groupon. He is also the chairman and a co-founder of venture fund firm, Lightbank. Tempus is a technology organization that has developed an operating system designed to fight cancer. In the year 2006, Eric Lefkofsky and his wife Liz founded the Lefkofsky Foundation- a private charitable organization established to help fund high-impact programs meant to improve people’s life in the community.
The operating system and library of clinical and molecular data that Tempus are currently working on are said to be the largest in the world. Tempus will make it possible for physicians and healthcare experts to deliver real-time, customized, and data driven treatment to cancer patients across the planet. Tempus uses patient’s genetic code to determine the right treatment for them. Presently, the technology is designed to help people suffering from pancreatic, lung and breast cancer, but they expect to include more types of cancer soon.
To Read More Click Here